{
  "nctId": "NCT00058422",
  "briefTitle": "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma",
  "officialTitle": "A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma",
  "protocolDocument": {
    "nctId": "NCT00058422",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2007-09-11",
    "uploadDate": "2020-09-23T10:49",
    "size": 1067182,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT00058422/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 65,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2003-02-10",
    "completionDate": "2019-11-14",
    "primaryCompletionDate": "2019-11-14",
    "firstSubmitDate": "2003-04-07",
    "firstPostDate": "2003-04-09"
  },
  "eligibilityCriteria": {
    "criteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed diffuse large B-cell lymphoma, including any of the following subtypes:\n\n  * Centroblastic\n  * Immunoblastic\n  * T-cell/histiocyte-rich\n  * Lymphomatoid granulomatosis type\n  * Anaplastic large B-cell\n  * Plasmablastic\n  * Mediastinal\n  * Intravascular large B-cell lymphoma\n* Previously untreated\n* High-intermediate or high-risk disease, defined by an age-adjusted international prognostic index score of 2 or 3 (with 1 point each assigned for a ECOG greater than 1/Karnofsky less than 80%, lactate dehydrogenase greater than normal, and stage III or IV)\n* Lymphomas with discordant histology and a diffuse large B-cell component are eligible\n* Must have an initial diagnostic specimen that is CD20+\n* At least Ann Arbor stage II disease\n\n  * No confinement of disease to an involved-field radiotherapy port (stage I or limited stage II disease)\n* Bidimensionally measurable disease with at least 1 lymph node at least 2.0 cm by 2.0 cm by physical examination, CT scan, or positron-emission tomography\n* Bone marrow cellularity greater than 15%\n* No known brain or leptomeningeal metastases\n* No primary effusion lymphomas\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 60 and over\\* NOTE: \\*Patients 60 to 65 years of age must be deemed ineligible for autologous stem cell transplantation\n\nPerformance status\n\n* Karnofsky 50-100%\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Bilirubin no greater than 2.0 mg/dL (except for Gilbert's disease)\n\nRenal\n\n* Creatinine no greater than 1.5 mg/dL\\* OR\n* Creatinine clearance greater than 50 mL/min\\* NOTE: \\*Patients not meeting either criterion but who have renal insufficiency directly related to lymphomatous involvement of the kidneys or renal collecting system are allowed\n\nCardiovascular\n\n* Cardiac ejection fraction at least 50% by echocardiogram\n* No acute myocardial infarction within the past 3 months\n* No uncontrolled hypertension\n* No New York Heart Association class III or IV congestive heart failure\n* No unstable angina pectoris\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* HIV negative\n* B12 and folate greater than the lower limit of normal\n* Transferrin saturation at least 15%\n* Ferritin greater than 10 Âµg/L\n* At least 6 weeks since prior RBC donation\n* No active seizure disorder\n\n  * Prior seizure disorder allowed if free of antiseizure medication and evidence of seizure activity for the past 5 years\n* No concurrent uncontrolled medical problems that would preclude administration of chemotherapy or radioimmunotherapy\n* No other concurrent malignancy treated with chemotherapy or radiotherapy except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 4 weeks since prior RBC transfusion\n* No prior biologic therapy\n* No other concurrent biologic therapy\n\nChemotherapy\n\n* No prior chemotherapy (one course of R-CHOP allowed)\n* No other concurrent standard or investigational chemotherapy\n\nEndocrine therapy\n\n* No more than 7 consecutive days of prior steroids (premedication allowed for prior intravenous contrast allergy)\n* No other concurrent corticosteroids\n\nRadiotherapy\n\n* No prior radiotherapy\n\nSurgery\n\n* Not specified",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "60 Years",
    "maximumAge": "120 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Overall Survival",
        "timeFrame": "2 years"
      },
      {
        "measure": "Progression-free Survival",
        "timeFrame": "2 years"
      },
      {
        "measure": "Event-free Survival",
        "timeFrame": "2 years"
      },
      {
        "measure": "Incidence of Adverse Experiences",
        "description": "Determine the incidence of adverse experiences, hematologic toxicity (WBC, hemoglobin, and platelet nadirs; and transfusion requirements), cardiac toxicity (incidence of left ventricular dysfunction and cardiomyopathy by echocardiography), and the development of human antimouse antibody/human anti-chimeric antibody in patients treated with this regimen.",
        "timeFrame": "2 years"
      }
    ],
    "secondary": [
      {
        "measure": "Conversion Rate to Complete Remission",
        "timeFrame": "2 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 4,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 45,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:51.934Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}